Overall, CB1Rs located in the periphery can be potentially considered as clinically relevant targets for therapeutics against obesity and its comorbidities, thus warranting further preclinical development and clinical testing of the peripherally restricted CB1R blockers. The gene discussed is CNR1; the disease is Obesity.